In January 2014, the FDA approved a BRAF/MEK inhibitor combination (dabrafenib/trametinib) for BRAF-mutant metastatic melanoma [10], which demonstrated higher response rates (76% versus 59%) and slightly longer median progression-free survival (PFS) than dabrafenib or vemurafenib monotherapies (9.4 versus 6.9 months) with less toxicity. The gene discussed is BRAF; the disease is metastatic melanoma.